Results of 36 month adjuvant trial of imatinib for high-risk GISTs

ASCO 2011 News reports that 36 months adjuvant Imatinib treatment for high risk GISTs improves recurrence-free survival (RFS) and even overall survival (OS). Click here to read the report.

Posted in GIST News.